Aldeyra Therapeutics (ALDX) to Announce Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.0775) per share and revenue of $31.33 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. On average, analysts expect Aldeyra Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Aldeyra Therapeutics Price Performance

Shares of Aldeyra Therapeutics stock opened at $1.53 on Tuesday. Aldeyra Therapeutics has a 52-week low of $1.07 and a 52-week high of $6.17. The firm has a market capitalization of $92.29 million, a PE ratio of -3.33 and a beta of 1.16. The company’s fifty day moving average price is $1.84 and its two-hundred day moving average price is $2.79.

Insider Transactions at Aldeyra Therapeutics

In other news, CEO Todd C. Brady purchased 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $1.67 per share, with a total value of $417,500.00. Following the acquisition, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at approximately $2,874,567.66. This trade represents a 16.99% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 11.80% of the stock is owned by corporate insiders.

Institutional Trading of Aldeyra Therapeutics

Several hedge funds have recently modified their holdings of ALDX. The Manufacturers Life Insurance Company increased its stake in shares of Aldeyra Therapeutics by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,074 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 1,972 shares during the period. Rhumbline Advisers boosted its holdings in Aldeyra Therapeutics by 2.7% in the second quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 2,018 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Aldeyra Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 152,787 shares of the biotechnology company’s stock worth $791,000 after purchasing an additional 2,309 shares during the period. Federation des caisses Desjardins du Quebec raised its holdings in Aldeyra Therapeutics by 25.8% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in Aldeyra Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 317,335 shares of the biotechnology company’s stock valued at $1,644,000 after purchasing an additional 2,607 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

Analysts Set New Price Targets

ALDX has been the topic of several recent research reports. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aldeyra Therapeutics presently has an average rating of “Hold” and a consensus target price of $5.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.